Overcoming a species-specificity barrier in development of an inhibitory antibody targeting a modulator of tumor stroma

Protein Engineering, Design & Selection : PEDS
Iris GrossmanDeborah Fass

Abstract

The secreted disulfide catalyst Quiescin sulfhydryl oxidase-1 (QSOX1) affects extracellular matrix organization and is overexpressed in various adenocarcinomas and associated stroma. Inhibition of extracellular human QSOX1 by a monoclonal antibody decreased tumor cell migration in a cell co-culture model and hence may have therapeutic potential. However, the species specificity of the QSOX1 monoclonal antibody has been a setback in assessing its utility as an anti-metastatic agent in vivo, a common problem in the antibody therapy industry. We therefore used structurally guided engineering to expand the antibody species specificity, improving its affinity toward mouse QSOX1 by at least four orders of magnitude. A crystal structure of the re-engineered variant, complexed with its mouse antigen, revealed that the antibody accomplishes dual-species targeting through altered contacts between its heavy and light chains, plus replacement of bulky aromatics by flexible side chains and versatile water-bridged polar interactions. In parallel, we produced a surrogate antibody targeting mouse QSOX1 that exhibits a new QSOX1 inhibition mode. This set of three QSOX1 inhibitory antibodies is compatible with various mouse models for pre-clinic...Continue Reading

References

Jun 29, 1999·Nature Biotechnology·P S Chowdhury, I Pastan
Mar 10, 2000·Biochemical and Biophysical Research Communications·D CoppockD A Cina-Poppe
Jan 31, 2003·Proteins·Simon C LovellDavid C Richardson
Dec 2, 2004·Acta Crystallographica. Section D, Biological Crystallography·Paul Emsley, Kevin Cowtan
Dec 21, 2004·Nucleic Acids Research·Marie-Paule LefrancGérard Lefranc
May 26, 2005·International Journal of Cancer. Journal International Du Cancer·Shigeyuki NagatoTakanori Ohnishi
Feb 24, 2006·Journal of Synchrotron Radiation·Ch BroennimannA Wagner
Dec 19, 2006·Nature Biotechnology·Consuelo Garcia-RodriguezJames D Marks
Apr 5, 2007·Nature Protocols·Ginger ChaoK Dane Wittrup
Jul 6, 2007·The New England Journal of Medicine·Clifford A Hudis
Apr 29, 2008·Nature Medicine·Greg FinakMorag Park
Nov 7, 2008·Methods in Molecular Biology·Brian K KayVeronica V Volgina
Aug 1, 2007·Journal of Applied Crystallography·Airlie J McCoyRandy J Read
May 30, 2009·Bioorganic & Medicinal Chemistry Letters·Christopher J FaradyCharles S Craik
Nov 26, 2009·Cell·Kandice R LeventalValerie M Weaver
Mar 31, 2010·Seminars in Hematology·George J Weiner
May 5, 2010·The Journal of Biological Chemistry·Hector M RodriguezVictoria Smith
Jan 1, 2008·Drug Development Research·Zhaofei LiuXiaoyuan Chen
Jan 25, 2011·Nature Reviews. Cancer·Giulio FranciaRobert S Kerbel
Apr 22, 2011·Toxicological Sciences : an Official Journal of the Society of Toxicology·Ian WakefieldTim Bourne
Mar 23, 2012·Nature Reviews. Cancer·Andrew M ScottLloyd J Old
Jul 18, 2012·Nature·Assaf AlonDeborah Fass
Jun 4, 2014·Protein Science : a Publication of the Protein Society·Yair GatDeborah Fass

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antibody Engineering

Antibody engineering technologies are constantly advancing to improve the clinical effectiveness of monoclonal and bispecific antibodies. Discover the latest research on Antibody Engineering here.

Related Papers

The Healthcare Forum Journal
D T Jaffe, C Scott
Controlled Clinical Trials
E N Brandt
Cellular Physiology and Biochemistry : International Journal of Experimental Cellular Physiology, Biochemistry, and Pharmacology
Chen-Ye ShiWen-Hui Lou
© 2021 Meta ULC. All rights reserved